Mouse xenograft models vs GEM models for human cancer therapeutics.
作者信息
Richmond Ann, Su Yingjun
出版信息
Dis Model Mech. 2008 Sep-Oct;1(2-3):78-82. doi: 10.1242/dmm.000976.
Abstract
摘要
相似文献
1
Mouse xenograft models vs GEM models for human cancer therapeutics.
Dis Model Mech. 2008 Sep-Oct;1(2-3):78-82. doi: 10.1242/dmm.000976.
2
The use of GEM models for experimental cancer therapeutics.
Dis Model Mech. 2008 Sep-Oct;1(2-3):83-6. doi: 10.1242/dmm.000570.
3
Rodent models for ovarian cancer research.
Int J Gynecol Cancer. 2003 Jul-Aug;13(4):405-12. doi: 10.1046/j.1525-1438.2003.13317.x.
4
Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee.
Cancer Res. 2004 Mar 15;64(6):2270-305. doi: 10.1158/0008-5472.can-03-0946.
5
Current status of animal-to-human transplantation.
Expert Opin Biol Ther. 2005 Nov;5(11):1415-20. doi: 10.1517/14712598.5.11.1415.
6
[Application and recent advances of laboratory mouse in human cancer research].
Ai Zheng. 2005 Feb;24(2):249-54.
7
Tumor models for efficacy determination.
Mol Cancer Ther. 2006 Oct;5(10):2435-43. doi: 10.1158/1535-7163.MCT-06-0391.
8
Application of genetically modified and cloned pigs in translational research.
J Reprod Dev. 2009 Jun;55(3):225-30. doi: 10.1262/jrd.20164.
9
Human Immune System Mice With Autologous Tumor for Modeling Cancer Immunotherapies.
Front Immunol. 2020 Oct 8;11:591669. doi: 10.3389/fimmu.2020.591669. eCollection 2020.
10
Conference summary: First International Workshop on Animal models of Prostate Cancer.
Prostate. 1998 Jun 15;36(1):47-8. doi: 10.1002/(sici)1097-0045(19980615)36:1<47::aid-pros8>3.0.co;2-8.
引用本文的文献
1
Understanding Tumor Dormancy: from Experimental Models to Mechanisms and Therapeutic Strategies.
Biomol Ther (Seoul). 2025 Sep 1;33(5):770-784. doi: 10.4062/biomolther.2025.056. Epub 2025 Aug 31.
2
New models for MPNST: establishment and comprehensive characterization of two tumor cell lines.
Cancer Cell Int. 2025 Jul 18;25(1):268. doi: 10.1186/s12935-025-03845-4.
3
Non-Coding RNAs in Cancer: Structure, Function, and Clinical Application.
Cancers (Basel). 2025 Feb 8;17(4):579. doi: 10.3390/cancers17040579.
4
Novel Concept of Electrocoagulation and Tumor Cell Implantation: Creation of Minimally Invasive Orthotopic Murine Model of Pancreatic Cancer.
JSLS. 2024 Oct-Dec;28(4). doi: 10.4293/JSLS.2024.00048. Epub 2025 Jan 17.
5
Evaluating anticancer potentials of potentized preparations in an in-vivo xenograft model.
J Ayurveda Integr Med. 2024 Nov-Dec;15(6):101015. doi: 10.1016/j.jaim.2024.101015. Epub 2024 Dec 2.
6
Bridging the gap between tumor and disease: Innovating cancer and glioma models.
J Exp Med. 2025 Jan 6;222(1). doi: 10.1084/jem.20220808. Epub 2024 Dec 3.
7
3D whole body preclinical micro-CT database of subcutaneous tumors in mice with annotations from 3 annotators.
Sci Data. 2024 Sep 19;11(1):1021. doi: 10.1038/s41597-024-03814-y.
8
Oncolytic Tanapoxvirus Variants Expressing mIL-2 and mCCL-2 Regress Human Pancreatic Cancer Xenografts in Nude Mice.
Biomedicines. 2024 Aug 12;12(8):1834. doi: 10.3390/biomedicines12081834.
9
BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models.
Nat Cancer. 2024 Oct;5(10):1479-1493. doi: 10.1038/s43018-024-00814-0. Epub 2024 Aug 23.
10
Biochemical hallmarks-targeting antineoplastic nanotherapeutics.
Bioact Mater. 2024 Jul 2;36:427-454. doi: 10.1016/j.bioactmat.2024.05.042. eCollection 2024 Jun.
本文引用的文献
1
Frontline treatment of multiple myeloma in elderly patients.
Blood Rev. 2008 Nov;22(6):303-9. doi: 10.1016/j.blre.2008.04.002. Epub 2008 Jun 11.
2
Establishing humanized mice using stem cells: maximizing the potential.
Clin Exp Immunol. 2008 Jun;152(3):406-14. doi: 10.1111/j.1365-2249.2008.03659.x. Epub 2008 Apr 24.
3
Establishment of human tumor xenografts in immunodeficient mice.
Nat Protoc. 2007;2(2):247-50. doi: 10.1038/nprot.2007.25.
4
Murine models to evaluate novel and conventional therapeutic strategies for cancer.
Am J Pathol. 2007 Mar;170(3):793-804. doi: 10.2353/ajpath.2007.060929.
5
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study.
Blood. 2006 Oct 1;108(7):2165-72. doi: 10.1182/blood-2006-04-019778. Epub 2006 Jun 13.
6
Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts.
Cancer Res. 2004 Jul 1;64(13):4601-10. doi: 10.1158/0008-5472.CAN-2879-2.
7
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
N Engl J Med. 2004 Jun 3;350(23):2335-42. doi: 10.1056/NEJMoa032691.
8
Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development.
Eur J Cancer. 2004 Apr;40(6):827-36. doi: 10.1016/j.ejca.2003.11.028.
9
Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved.
Cancer Biol Ther. 2003 Jul-Aug;2(4 Suppl 1):S134-9.
10
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.
N Engl J Med. 2003 Jul 31;349(5):427-34. doi: 10.1056/NEJMoa021491.
Zotero 插件